Agency / Source: Mayuka Labs (P) Ltd

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Mayuka Labs R&D Centre Receives DSIR Recognition - New Delhi based Mayuka Labs Private Limited has received recognition for its in-house research & development facility from the department of scientific and industrial research (DSIR) under the ministry of science and technology, Government of India
Mayuka Labs R&D Centre Receives DSIR Recognition

 

PRZOOM - /newswire/ - New Delhi, India, 2009/01/25 - New Delhi based Mayuka Labs Private Limited has received recognition for its in-house research & development facility from the department of scientific and industrial research (DSIR) under the ministry of science and technology, Government of India.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

With twenty one scientists working round the clock at it's R&D and Pilot unit at Nacharam, Mayuka Labs has crossed this milestone in its first year of operations. The company has filed two international PCT patents in 2008 and is working on new process technologies on 12 different molecules. The companies customer base ranges from big pharma clients like Boehringer Ingelheim to leading generic companies like Mylan subsidiary Matrix Labs, Dr. Reddy’s and Unimark Remedies.

"We create value for our customers through innovative new processes. As Thomas Friedman put it, this is a flat and deeply interconnected world and our R&D teams work 24 by 7 to cater to customers across the world. The DSIR recognition for our R&D, is a key milestone as we continue to drive efficiencies in the Custom Research, Custom Synthesis and Custom Manufacturing space“, said Dr.Chandra Sekhar N K, Chairman and Managing Director, Mayuka Labs.

With this accreditation, Mayuka Labs is entitled to receive support from government establishments such as Council of Scientific & Industrial Research (CSIR), Department of Biotechnology (DBT) and the Department of Science and Technology (DST) for its projects.

According to the DSIR website there are only one thousand two hundred and forty seven companies across all industries, including research labs set up by multi national companies which are recognized by DSIR in India. Within the pharma and biotech space, there are less than two hundred. Mayuka Labs is now a part of this select group.

The Government recognition of its R&D center, apart from recognizing the innovative work being done by Mayuka scientists enables the company to enjoy a weighted tax deduction of 150% on its R &D expenses along with complete exemption of duties on import of materials, equipment and machinery for R&D purpose.

About Mayuka Labs

New Delhi based Mayuka Labs (mayukalabs.com) was established in July, 2007 and set up its Research Labs in October 2007. The company is funded by US investors and offers Custom Research, Custom Synthesis and Custom Manufacturing services to innovator and generic companies across the world. Its R&D and pilot plant is in Nacharam Hyderabad and its API facility is located in Kopargaon, Maharashtra.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Mayuka Labs (P) Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Mayuka Labs R&D Centre Receives DSIR Recognition

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Dr. Chandra Sekhar - MayukaLabs.com 
+91 11 46523601 chandra[.]mayukalabs.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Mayuka Labs (P) Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From Mayuka Labs (P) Ltd / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Press Releases:

Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
Ono Pharma Announces Transfer of the Manufacturing and Marketing Approval Authorization for Opalmon® Tablets and Prostandin® Ointment
Ono Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory
SCHOTT Pharma Launches EVERIC® Lyo & Amber Vials for Light-sensitive ADCs
Arbitration Tribunal Upholds Ipsen’s Termination of R&D Agreement with Galderma
New Data Reinforces Ipsen’s Commitment to Bringing Solutions and Addressing Care Gaps in Neurological Diseases At TOXINS
Opdivo® Intravenous Infusion Approved in Taiwan in Combination with Yervoy® for the Treatment of Adult Patients
U.S. FDA Grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in First Line Unfit Acute Myeloid Leukemia
Additional Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer in South Korea
BostonGene Recognized by Frost & Sullivan for 2025 Global Technology Innovation Leadership in AI-Driven Precision Oncology Solutions

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  BizJobs.com

Visit  RightITnow, Inc.







 
  ©2005-2026 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today